Potential contribution of aspirin to cancer control programmes by Morgan, G
Potential contribution of aspirin to cancer control programmes 
G Morgan 
Welsh Aspirin Group Secretary, 41 Fforrd Beck, Gowerton, Swansea, Wales SA4 3GE, UK 
Abstract 
Chemoprevention describes the potential of chemicals to intervene and block multi-stage carcinogenesis. Aspirin (acetylsalicylate) is 
showing cancer chemopreventive potential and the medicine has public health potential given that low doses also reduce the risk of 
cardiovascular events by up to 30%. Whilst recognizing that aspirin has undesirable effects, such as increasing the risk of stomach 
bleeding, perhaps the medicine may compliment other cancer control programmes such as screening and lifestyle measures. 
Furthermore, perhaps the cancer chemopreventive potential of aspirin might be mediated, at least in part, by salicylate, which is present 
in fruits and vegetables. Salicylate might, therefore, be considered to be a nutraceutical. Furthermore, there are a number of matters that 
arise including the potential for the public health field to further advocate the self-care preventive agenda, which might include aspirin. 
Perhaps, it is now timely for a conference on the public health potential of aspirin to be convened.
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Introduction 
Chemoprevention describes the potential of pharmaceutically 
manufactured or naturally produced chemicals to intervene and 
block the complex processes of cancer formation, so called 
multi-stage carcinogenesis [1]. A number of chemicals with 
cancer chemopreventive potential have been reported in the 
literature, such as curcumin [2] and ginseng [3]. Some 
medicines in clinical use also have cancer chemopreventive 
properties, for example retinoids decrease the numbers of 
squamous cell skin carcinomas in psoriasis patients [4], and 
tamoxifen is used for breast cancer risk reduction in patients in 
remission from the disease [5].  
Aspirin (acetylsalicylic acid) is an easily obtainable and 
inexpensive pharmaceutical medicine that is widely used to 
treat a number of conditions [6]. The chemical of acetylsalicylic 
acid was first synthesized in 1899 by Bayer Pharmaceuticals in 
Germany [7] and mass produced under the commercial name of 
aspirin. In the intervening century, aspirin has become one of 
the most widely used medicines around the world and it is also 
showing cancer chemopreventive potential [8]. The interest in 
this potential extends back over more than a decade and aspirin 
and other non-steroidal anti-inflammatory drugs (NSAIDs) were 
the subject of the first International Agency for Research on 
Cancer (IARC) scientific evaluation on cancer chemoprevention 
[9].  
Since the IARC evaluation, selective NSAIDs have been 
introduced into clinical use in an attempt increase the 
effectiveness of this class of medicines. Some of these selective 
agents, such as celecoxib, offer a chemopreventive rather than 
surgical option against pre-cancerous adenomatous polyps in 
the bowel [10,11]. However, selective NSAIDs are associated 
with an increased risk of cardiovascular events [10,11], which 
raises questions about the benefit-versus-risk balance of these 
medicines. Such benefit-versus-risk questions would appear to 
make selective NSAIDs unsuitable for cancer chemoprevention 
in the general population.  
It might be reasonably argued that of all existing and emerging 
cancer chemopreventive agents, aspirin has the greatest public 
health potential. Low-dose aspirin prophylaxis, 70–150 mg/d, 
reduces the risk of cardiovascular events by up to 30% [12]. 
Furthermore, aspirin is already well known and widely used in 
the general population as well as providing a benchmark to 
measure the effectiveness of other medicines, such as statins 
[13]. However, aspirin also has undesirable effects [14], most 
notably irritation and bleeding of the stomach. Occasionally, 
these undesirable effects can be serious and may even be fatal 
in some cases [14]. Aspirin prophylaxis against cardiovascular 
events therefore balances benefit and risk. The emerging 
evidence on aspirin and cancer chemoprevention, particularly 
bowel cancer, is also a relevant consideration in this benefit and 
risk assessment.  
 
Aspirin, salicylates and cancer 
Randomized controlled trials (RCTs) provide evidence that 
aspirin reduces recurrence of either adenomatous polyps or 
pathological changes associated with an increased risk of bowel 
cancer [15,16]. The limitation to the RCTs, however, is that they 
only use a proxy outcome measure rather than cancer as the 
end point. With reference to RCTs on aspirin and cancer, there 
is a variation in results between trials. Two trials in the United 
States provided no evidence that aspirin on alternate days 
reduces cancer risk [17,18]. By contrast, a re-evaluation of two 
trials in the United Kingdom with daily aspirin found that ten 
years of use reduced the risk of bowel cancer by 40% [19]. 
Although different doses were used in the four trials, one of the 
US trials and one of the UK trials used similar doses of 325 and 
300 mg, respectively. Furthermore, one of the US trials also had 
a follow-up of ten years, which raises questions about the dose 
and duration effect of aspirin.  
Possibly, the difference in the results between the US and UK 
trials might be due, at least in part, to the different dosing 
regimes of alternate days versus daily, respectively. Possibly, 
daily aspirin exposure over ten years might be required to 
reduce the risk of bowel cancer. Furthermore, the current 
evidence suggests that perhaps doses of aspirin higher than 
those used routinely for cardiovascular event prophylaxis might 
be required for chemoprevention. The risk of undesirable effects 
from aspirin increases with both age and dose. This is an 
important point given that many cancers, such as bowel cancer, 
tend to have rising incidence in the general population with 
increasing age. 
Perhaps, there might also be another dimension with the 
possible cancer chemopreventive effects of aspirin. The 
potential cancer chemopreventive effects might be related, at 
least in part, to salicylate. Humans are exposed to salicylate 
through eating fruit and vegetables, and it has been suggested 
that perhaps salicylate might be beneficial to health [20]. 
Salicylate has anti-oxidant effects, anti-inflammatory properties 
and induces programmed cell death or apoptosis in cancer cells 
[21]. More evidence is needed on the effect of salicylate on 
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human health generally and cancer chemoprevention 
specifically. This also raises a wider issue of whether 
components of food can be helpful in reducing disease risk.  
Nutraceuticals are a food, or part of a food, that provides 
medical or health benefits, including the prevention or possibly 
treatment of a disease [22]. The term nutraceutical is a hybrid of 
nutrition and pharmaceutical [23]. It has been suggested that a 
‘nutraceutical a day may keep the doctor away’ and that 
‘consumers are turning increasingly to food supplements 
to improve well being when pharmaceuticals fail’ [23]. This 
however raises further issues given that there is evidence that 
supplements of some vitamins may increase the risk of 
premature mortality [24]. A clear scientific definition of the 
criteria for vitamin status and also the introduction of a 
regulatory system for their supply and demand might be some 
of the developments taken forward.   
In future, there might be more attention given to the potential 
value of nutraceuticals in the promotion of human health. There 
are numerous examples of nutraceuticals published in the 
literature and, for example, these have relevance to the 
chemoprevention of stomach [25] and prostate [26] cancers. 
Poly-unsaturated fatty acids (PUFAs) have anti-inflammatory 
effects [27] and since chronic low-level inflammation can 
increase the risk of some cancers [28], perhaps both PUFAs 
and salicylates may have cancer chemopreventive properties. 
As a related point, inflammation in vascular tissue also appears 
to be an aetiological factor in cardiovascular events [29,30].   
Research therefore appears to be warranted on whether 
salicylate derived from fruit and vegetables has nutraceutical 
properties. Such research may contribute to a wider debate on 
dietary changes in the population. So-called epidemiological 
diet transition suggests that populations are eating more 
processed foods and less fruit and vegetables [31]. Possibly, 
reduced dietary intake of salicylate in the population might 
predispose some individuals to increased cancer risk and 
perhaps aspirin might counteract this deficiency. This may also 
provide further reasons to promote the intake of salicylate rich 
fruit and vegetables, such as berries and organic produce, in 
the general population. However, it also needs to be recognized 
that chemoprevention might be only one element of cancer 
control programmes, alongside other measures such as 
screening and lifestyle approaches.  
  
 
Other cancer control programmes 
Screening is one of the important cancer control programmes. 
In screening, individuals are asked a question or offered a test 
to identify those who might be helped by further investigation. 
Screening programmes include breast and bowel cancers. 
Taking the former, a review of breast cancer screening by the 
evidence-based body, the Cochrane Collaboration, suggested 
that the programme of mammography in women over the age of 
50 years lowers risk of breast cancer mortality by about 15% 
[32]. However, the review also highlighted that there are some 
undesirable aspects of breast cancer screening for some 
women. This includes inaccurate results leading to unnecessary 
treatment for some women. The review called for women who 
are invited to breast cancer screening to be 'fully informed of 
both benefits and harms'. This statement also appears to be 
pertinent to aspirin prophylaxis since the medicine also has 
benefits and risks. There is also some promising evidence that 
aspirin may also reduce the risk of breast cancer [33] although, 
similar to bowel cancer, low doses on alternate days may not 
have chemopreventive effects [34].  
One of the limitations to the breast cancer screening 
programme is that younger women at increased risk of the 
disease are not routinely included [35]. Family history of breast 
cancer is a strong predictor of disease development and is one 
of the factors used in compiling at risk registers for women. 
Such registers can then be used to follow up women at 
increased risk of breast cancer and in addition, primary care has 
been highlighted as a potential setting to identify those who may 
have hereditary predisposition to the disease, such as BRCA 
mutation carriers [36].  
With respect to the bowel cancer screening programme, this 
includes the faecal occult blood test (FOBT). Similar to the 
breast cancer programme, a Cochrane Collaboration review has 
highlighted the potential undesirable aspects of inaccurate 
results and unnecessary treatment [37]. Bowel cancer 
screening programmes vary in their delivery, but they also 
usually include individuals over the age of 50 years. In addition, 
younger high-risk patients who are genetically predisposed to 
bowel cancer are usually identifiable, and in the United Kingdom 
they are often registered with a Regional Genetics Centre. High-
risk patients include those with genetic conditions, including 
hereditary non-polyposis colorectal cancer (HNPCC) and 
familial adenomatous polyposis (FAP). HNPCC patients usually 
receive surveillance of the bowel from the age of 25 years, 
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whilst in the case of FAP, prophylactic surgery before the age of 
25 years is usually recommended [38]. 
One of the issues with the bowel cancer screening programme 
relates to the screening algorithm based upon FOBT and 
colonoscopy for those testing positive, with perhaps radiology 
also contributing in future [39]. Although FOBT is a simple and 
non-invasive test, it has poor sensitivity and may only detect a 
bleeding lesion rather than cancerous changes [40]. 
Furthermore, colonoscopy rather than FOBT may be the most 
appropriate initial investigation for individuals with higher than 
average risk of bowel cancer [41]. In developing bowel cancer 
screening programmes, considerations include patient 
preferences, likelihood of adherence to follow up and resources 
available [42].  
Another issue with the bowel cancer screening programme 
relates to uptake. For example in the UK Bowel Cancer 
Screening Pilot Programme, nearly 130,000 men and women 
aged 50–69 years were invited to participate and uptake ranged 
from 61% in the wealthiest areas to 37% in the poorest areas 
[43]. Does this mean that screening should be more intensively 
targeted in the areas of lowest uptake? This possibility does 
deserve to be considered although the UK Bowel Cancer 
Screening Programme is already financially constrained [44] so 
intensive targeting may not be a possibility within available 
resources.   
Self-care is important [45] and perhaps consideration could be 
given to the potential contribution of aspirin to bowel cancer 
screening programmes. Individuals who have pre-cancerous 
lesions removed from the bowel in the programme might at 
least be offered the evidence on the benefits and risks of low-
dose aspirin given that this might reduce the risk of subsequent 
pathological changes associated with bowel cancer 
development. There is an important related dimension to this. 
 Many individuals at the age of 50 have a risk of cardiovascular 
events in which considering taking low-dose aspirin prophylaxis 
may be a reasonable option [46,47], although this possibility has 
been debated [48]. It may be recognized, however, that 
cardiovascular events and cancer are the biggest causes of 
disease, disability and death in the population, and so increased 
use of aspirin might confer considerable public health benefits if 
targeted appropriately [49]. 
It may be reasonably concluded that cancer screening 
programmes do not represent a complete solution to cancer 
control and do have negative aspects as well. So in addition to 
screening programmes, there are also lifestyle approaches to 
cancer control. For example the deleterious effects of smoking 
on health and the importance of cessation have been well 
documented, especially within the context of deprivation and 
low socio-economic status in which the highest smoking rates 
are found [50]. Gender may also play an important role as well, 
since there is suggestive evidence that women might be more 
susceptible to developing smoking-related illnesses compared 
with men [51]. Whilst smoking cessation programmes are 
important, other measures such as advertising bans on tobacco 
products might also contribute to cancer control programmes 
[52].  
Alcohol consumption is sometimes closely associated with 
smoking [53] and even moderate alcohol consumption may 
increase the risk of some cancers, such as breast. This 
increased risk, however, conflicts with health promotion advice 
on moderate alcohol consumption for the cardiovascular 
benefits [54]. Cancer control programmes therefore need to find 
a balance between the benefits and risks of alcohol 
consumption, which raises wider social considerations.  
Diet is also important, and IARC are co-ordinating the European 
Prospective Investigation into Cancer and Nutrition study across 
ten countries. This includes more than half a million participants 
of whom 70% are men between the ages of 35 and 70 years. 
This study shows the impact of diet on cancer risk [55], for 
example, vegetables, which contain salicylate, appear to reduce 
the risk of stomach cancer. In addition, red meat appears to 
increase the risk of bowel cancer whilst fish, which contain 
PUFAs, may decrease the risk of the disease. Furthermore, 
there is evidence that obesity is a risk factor for cancer as well, 
for example breast and bowel cancers in post-menopausal 
women [56]. This highlights the potential importance of both diet 
and exercise in reducing cancer risk through a process of 
weight control. 
However, two publications, of relevance to weight control, 
illustrate the complexity of lifestyle approaches to reducing the 
risk of cancer. In November 2007, a World Cancer Research 
Fund (WRCF) report set out ten rules for preventing cancer [57]. 
One of these rules was having a Body Mass Index (BMI) of 25 
or lower. Shortly after the publication of WRCF report, the US 
Centers for Disease Control and Prevention (CDC&P) also 
presented cancer control recommendations [58]. This report 
provided evidence that being underweight and obesity carry 
increased risks of mortality, albeit from different causes. 
Furthermore, it was suggested that being overweight, defined 
as having a BMI of between 25–30, was associated with 
decreased mortality overall and was not associated with 
mortality from either cancer or cardiovascular causes.  
With both of the WRCF and CDC&P reports, the media 
coverage was extensive and to some extent contradictory. This 
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contradiction appears to be consistent with the comment of the 
Public Library of Science Medical Editors, who stated: ‘It is not 
always easy for the public to determine what is best given 
the barrage of information forced on them every week’ [59]. 
Lessons from other medical issues also highlight the need for 
health professionals to provide the general public with clear and 
consistent information. For example, in 1998, a controversial 
study linked measles, mumps and rubella (MMR) with autism 
[60], and this was widely reported in the media. Since 1998, the 
uptake of MMR vaccination has declined and a study on the 
reasons has suggested that inadequate information from 
healthcare professionals was an important contributory factor 
[61].  
If lifestyle approaches to cancer control are to be fully 
maximized then it is important for the general public to be given 
clear and consistent information by healthcare professionals. 
This is pertinent to aspirin. If the general public is to be given 
clear and consistent information on ways to reduce the risk of 
cancer, at what stage is the emerging evidence on aspirin 
systematically put into the public domain to allow individuals to 
make their own informed decisions on whether or not to take 
aspirin? This is a far reaching question that deserves to be 
debated further, particularly since the information on aspirin and 
cancer is already being reported in the media with differing 
levels of accuracy.   
For the purposes of comprehension, the use of vaccines to 
reduce cancer risk also merits brief mention to illustrate the 
broader context of cancer control programmes. For example, 
the human papillomavirus (HPV) is a sexually transmitted 
infection, which causes genital warts and some cancers, most 
notably cervical cancer. HPV vaccination programmes to reduce 
the risk of cervical cancer may be seen as a complement rather 
than an alternative to the screening programme for this disease 
[62]. Although some issues still need to be given further 
consideration with HPV vaccination, including the duration of 
protection [63], the broader point with wider application is that 
different cancer control approaches can be combined. 
  
From preventive self-care to public health 
policy 
The population is ageing and with individuals living longer, 
service provision is becoming increasingly community based 
[64] and multi-disciplinary [65] in some countries. In addition to 
the changing patterns of service provision, self-care is important  
[66], and this has the potential to improve the management of 
long-term conditions whilst also taking account of patient safety 
issues [67]. The potential of self-care, however, also extends to 
prevention as well as self-examination for the early identification 
of testicular cancer. It has also been stated that an ’ounce of 
prevention is worth a pound of cure’ and one way to achieve 
this may be to ‘offer financial incentives to people for 
healthy behaviour’ [68]. This is a controversial suggestion that 
could have far reaching implications for the delivery of public 
health policy.  
Public health may be considered as improving and protecting 
the health of groups of people, or populations, rather than 
treating individual patients. Public health has a proud tradition 
[69], for example in 1848, the Public Health Act for England and 
Wales [70] and Sir Edwin Chadwick, the driving force behind 
this Act, has been described as leaving a ‘monumental’ public 
health legacy [71]. Although some have argued that public 
health is in decline [72,73], the framework for the delivery of 
public health continues to evolve [74]. So perhaps there is an 
opportunity for the field of public health to further advocate the 
self-care preventive agenda, which might include aspirin. This 
could be progressed through collaborative working, which has 
been suggested as an important leadership issue in public 
health [75], for example in the so-called communities of practice 
with other professional groups [76]. 
It is reasonable to acknowledge that there is a considerable 
amount of knowledge on lifestyle risk factors for disease. For 
example a cohort study of 20,000 men and women aged 45–79 
years in east England is part of the IARC European Prospective 
Investigation on Cancer and Nutrition study. The study has 
suggested that regular exercise, 1–14 units of alcohol per week 
(unit = glass of wine or half pint of beer), eating five servings of 
fruits and vegetables per day and not currently smoking might 
prolong life by 14 years [77]. The public health potential of 
aspirin might be viewed as complement rather than an 
alternative or competitor to these beneficial lifestyle factors. 
However, the potential increased use of the medicine still raises 
a number of debates and ethical considerations [78], some of 
which may be presented to the public through the media. 
In balance to the two illustrations of media interest in health 
issues presented previously, it may be acknowledged that 
media involvement can be beneficial. For example, in Wales, 
the bowel cancer screening programme was launched at the 
end of October 2008. Television advertising was used as one of 
the methods to raise awareness of both the disease and the 
screening programme. Perhaps the wider lesson is that close
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working between media and health professionals can usefully 
disseminate accurate information to the benefit of the targeted 
population.   
  
Conclusion 
Currently, there is a trend towards an increase in life 
expectancy in the population, which appears to be attributable 
to improvements in medicine, public health and agriculture [79]. 
The two biggest causes of disease, disability and death in the 
population are cardiovascular disease and cancer, and 
increased aspirin use might reduce their burden. The increased 
use of aspirin may in future form part of cancer control 
programmes and the increased use of the medicine in the 
population may confer considerable public health benefits. 
These benefits could lead to a further shift towards preventive 
self-care, which might in turn help reduce the pressure on 
healthcare services. Indeed, even the iconic National Health
Service in the United Kingdom has limitations in caring for the 
population over the age of 50 years [80]. So there might be 
considerable population need, defined by health economists as 
capacity to benefit from treatment [81], for increased aspirin 
use. However, the potential benefits from increased aspirin use 
in the population need to be balanced by the undesirable effects 
of the medicine. Perhaps, it is time for another conference on 
the public health potential of aspirin to be convened [82] so that 
this important matter can be given further consideration with a 
view to appropriate policy responses being developed in 
accordance with the evidence. 
Part of this evidence base will need to take account of the 
existing levels of aspirin use within the population [83], which 
may require some surveys to be undertaken in some countries.  
In addition, the natural exposure of nutraceutical salicylate 
through the diet might also contribute to cancer control 
programmes in future and further research is required.  
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